BRPI1009585A2 - peptídeo, ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um peptídeo, aparelhagem médica ou implante, e, planta transgênica - Google Patents

peptídeo, ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um peptídeo, aparelhagem médica ou implante, e, planta transgênica

Info

Publication number
BRPI1009585A2
BRPI1009585A2 BRPI1009585A BRPI1009585A BRPI1009585A2 BR PI1009585 A2 BRPI1009585 A2 BR PI1009585A2 BR PI1009585 A BRPI1009585 A BR PI1009585A BR PI1009585 A BRPI1009585 A BR PI1009585A BR PI1009585 A2 BRPI1009585 A2 BR PI1009585A2
Authority
BR
Brazil
Prior art keywords
peptide
implant
nucleic acid
pharmaceutical composition
host cell
Prior art date
Application number
BRPI1009585A
Other languages
English (en)
Portuguese (pt)
Inventor
Ali Ladram
Bruno Oury
Denis Sereno
Feten Abbassi
Mohamed Amiche
Pierre Nicolas
Original Assignee
Univ Pierre Marie Curie Paris 6 ; Inst De Rech Pour Le Developpment; Ct Nat De La Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pierre Marie Curie Paris 6 ; Inst De Rech Pour Le Developpment; Ct Nat De La Rech Scient filed Critical Univ Pierre Marie Curie Paris 6 ; Inst De Rech Pour Le Developpment; Ct Nat De La Rech Scient
Publication of BRPI1009585A2 publication Critical patent/BRPI1009585A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8282—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8283—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI1009585A 2009-03-19 2010-03-18 peptídeo, ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um peptídeo, aparelhagem médica ou implante, e, planta transgênica BRPI1009585A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0951768A FR2943345B1 (fr) 2009-03-19 2009-03-19 Analogues de la temporine-sha et leurs utilisations
PCT/FR2010/050487 WO2010106293A1 (fr) 2009-03-19 2010-03-18 Analogues de la temporine-sha et leurs utilisations

Publications (1)

Publication Number Publication Date
BRPI1009585A2 true BRPI1009585A2 (pt) 2016-03-08

Family

ID=41066385

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009585A BRPI1009585A2 (pt) 2009-03-19 2010-03-18 peptídeo, ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um peptídeo, aparelhagem médica ou implante, e, planta transgênica

Country Status (7)

Country Link
US (1) US9522942B2 (cg-RX-API-DMAC7.html)
EP (1) EP2408806A1 (cg-RX-API-DMAC7.html)
JP (1) JP5713211B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009585A2 (cg-RX-API-DMAC7.html)
CA (1) CA2755472C (cg-RX-API-DMAC7.html)
FR (1) FR2943345B1 (cg-RX-API-DMAC7.html)
WO (1) WO2010106293A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3385343B2 (ja) 1996-12-26 2003-03-10 Ｎｔｎ株式会社 トリポード型等速自在継手
EP2853538A1 (en) * 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
DK3087092T3 (en) * 2013-12-12 2018-11-12 Academisch Ziekenhuis Leiden ANTIMICROBIAL PEPTID AND APPLICATIONS THEREOF
CN106117333A (zh) * 2016-07-06 2016-11-16 贵州师范大学 合江棘蛙皮肤抗菌肽及其编码序列的基因及原核表达
US10550155B2 (en) * 2018-03-27 2020-02-04 Farzana Shaheen Anticancer peptides
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013958A1 (en) * 1991-02-06 1992-08-20 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5916872A (en) * 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity

Also Published As

Publication number Publication date
US9522942B2 (en) 2016-12-20
JP5713211B2 (ja) 2015-05-07
FR2943345A1 (fr) 2010-09-24
EP2408806A1 (fr) 2012-01-25
CA2755472C (fr) 2017-11-21
WO2010106293A1 (fr) 2010-09-23
CA2755472A1 (fr) 2010-09-23
JP2012520665A (ja) 2012-09-10
FR2943345B1 (fr) 2011-05-27
US20120005790A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
IL294095A (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
BRPI0916560A2 (pt) análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
BRPI1009585A2 (pt) peptídeo, ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um peptídeo, aparelhagem médica ou implante, e, planta transgênica
EP2655604A4 (en) ADENOVIRUS SEROTYPE-26 AND SEROTYPE-35 FILOVIRUS VACCINES
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
EP2467010A4 (en) Aad-1 event das-40278-9, related transgenic corn lines, and event-specific identification thereof
DK3175711T3 (da) Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf
PL3287525T3 (pl) Preparaty RNA zawierające oczyszczony zmodyfikowany RNA do przeprogramowywania komórek
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
BR112012017428A2 (pt) sistema de distribuição de fluido ára cuidados bucais
DK2073860T3 (da) Lægemiddelfrigivende coatinger til medicinske indretninger
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
EP2623068A4 (en) Tissue protective device for coronary sinus and tricuspid valve, knot delivery device, and device for mitral valve cerclage, containing same
EP2244720A4 (en) POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM
EP2416754A4 (en) UV-PROTECTION COMPOSITION AND METHOD OF USE
ZA201205840B (en) Pesticidal mixtures containing isoxazoline derivatives and insecticide or nematoicidal biological agent
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
EP2555751A4 (en) MEDICAL DEVICES WITH MEDICAMENTS AND METHOD FOR THEIR MANUFACTURE AND USE
DK3646823T3 (da) System omfattende en proteseklap og et afgivelseskateter
PL2131668T3 (pl) Ochronny hydrokoloid dla składników czynnych
EP2470144A4 (en) PATIENT TRANSPORTER
BRPI1006040A2 (pt) uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
EP2371263B8 (en) Capsule medical device guidance system
EP2464312A4 (en) MEDICAL IMPLANT SYSTEM
DK2394578T3 (da) Vægtbaseret kalibreringssystem til et trykfølsomt kateter

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 10A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2558 DE 14/01/2020.